Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial

被引：0
|
作者：
Preiss, David [1 ]
Herrington, William [1 ]
Haynes, Richard [1 ]
机构：
[1] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England
来源：
CIRCULATION | 2022年 / 146卷 / 25期
关键词：
Sodium glucose co-transporter 2 inhibitors Chronic kidney disease; Cardiovascular disease Clinical trials;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
19464
引用
收藏
页码：E577 / E577
页数：1
相关论文
共 50 条
  • [1] Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
    Judge, Parminder K.
    Staplin, Natalie
    Mayne, Kaitlin J.
    Wanner, Christoph
    Green, Jennifer B.
    Hauske, Sibylle J.
    Emberson, Jonathan R.
    Preiss, David
    Ng, Sarah Y. A.
    Roddick, Alistair J.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen Jiun
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Massey, Dan
    Landray, Martin J.
    Baigent, Colin
    Haynes, Richard
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 51 - 60
  • [2] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial
    Staplin, Natalie
    Haynes, Richard
    Judge, Parminder K.
    Wanner, Christoph
    Green, Jennifer B.
    Emberson, Jonathan R.
    Preiss, David
    Mayne, Kaitlin J.
    Ng, Sarah Y. A.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Petrini, Michaela
    Seide, Svenja
    Landray, Martin J.
    Baigent, Colin
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 39 - 50
  • [3] EFFECTS OF EMPAGLIFLOZIN ON FLUID OVERLOAD IN CHRONIC KIDNEY DISEASE: AN EMPA-KIDNEY BIOIMPEDANCE SUBSTUDY
    Mayne, Kaitlin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I49 - I50
  • [4] Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY
    Nangaku, Masaomi
    Herrington, William G.
    Goto, Shinya
    Maruyama, Shoichi
    Kashihara, Naoki
    Ueki, Kohjiro
    Wada, Jun
    Watada, Hirotaka
    Nakashima, Eitaro
    Lee, Ryonfa
    Massey, Dan
    Mayne, Kaitlin J.
    Tomita, Aiko
    Haynes, Richard
    Hauske, Sibylle J.
    Kadowaki, Takashi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (06) : 588 - 595
  • [5] Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial
    Harinala Groyer
    Romain Supiot
    Jean Tardu
    Nicolas Virely
    Marine Sivignon
    Denis San
    Pierre Lévy
    Anastasia Ustyugova
    Ziad A. Massy
    Clinical Drug Investigation, 2024, 44 (11) : 811 - 828
  • [6] The impact of multimorbidity on the effects of empagliflozin in chronic kidney disease (CKD): exploratory analyses from the EMPA-KIDNEY trial
    Mayne, Kaitlin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I112 - I114
  • [7] Empagliflozin for the treatment of chronic kidney disease EMPA Kidney Study
    Feldkamp, Thorsten
    NEPHROLOGIE, 2023, 18 (03): : 179 - 181
  • [8] Effect of empagliflozin on all-cause hospitalization in EMPA-KIDNEY
    Uster, Anastasia
    Desai, Nihar
    Navaneethan, Sankar
    Pfarr, Egon
    Mazo, Anna Rita
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 153
  • [9] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial. (vol 12, pg 39, 2024)
    Staplin, N.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : e16 - e16
  • [10] Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    George, Jyothis
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wanner, Christoph
    Hauske, Sibylle
    DIABETES, 2019, 68
12345